KCM Investment Advisors LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,883 shares of the medical research company’s stock after acquiring an additional 869 shares during the quarter. KCM Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $737,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Icon Wealth Partners LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $105,000. Bank of Nova Scotia Trust Co. bought a new position in Thermo Fisher Scientific in the third quarter valued at approximately $106,000. Keeler Thomas Management LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $106,000. Virtue Capital Management LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $127,000. Finally, Premia Global Advisors LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $131,000. 87.63% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have weighed in on TMO shares. Leerink Swann reaffirmed an “outperform” rating and set a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Evercore ISI started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price on the stock. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Barclays boosted their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $222.29.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. Thermo Fisher Scientific’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.41 earnings per share. research analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s payout ratio is 12.14%.
In other news, SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares in the company, valued at $13,285,478.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now owns 334,622 shares in the company, valued at approximately $70,324,159.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 88,827 shares of company stock worth $19,012,672. 0.49% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3295803/thermo-fisher-scientific-inc-tmo-position-lifted-by-kcm-investment-advisors-llc.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.